What the new Medicare card will look like

CMS has released the design of the new Medicare cards which beneficiaries will begin to receive next year, containing a randomly assigned number to replace the current one based off a patient’s Social Security number.

The card will include this new number, the Medicare Beneficiary Identifier (MBI), below the patient’s name, along with the Medicare services the beneficiary is entitled to receive (Part A, Part B, etc.) and the date their coverage had started.

“The goal of the initiative to remove Social Security numbers from Medicare cards is to help prevent fraud, combat identify theft, and safeguard taxpayer dollars,” CMS Administrator Seema Verma, MPH, said in a statement. “We’re very excited to share the new design.”

As previously announced by CMS, beneficiaries will begin receiving their new cards in April 2018, meeting a deadline set by Congress to replace all the cards by April 2019. For a 21-month period after the rollout begins, providers will accept both the new and old Medicare cards.

Having a Social Security-based number has made Medicare beneficiaries popular targets for identity theft, according to CMS, with reported incidents among people aged 65 or older increasing from 2.1 million to 2.6 million between 2012 and 2014.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.